Valeant: Another Fine Mess
This article was originally published in Scrip
Michael Pearson's "Leap Day" return to Valeant Pharmaceuticals International Inc. was supposed to be a victory for the CEO and his firm after he'd spent the past few months on sick leave recovering from a severe bout of pneumonia.
You may also be interested in...
Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
At first glance, giving back Addyi to the original owners for next to nothing looks like a complete disaster but investors are relieved debt-ridden Valeant has managed to offload another asset.